AI assistant
Sending…
NovaBay Pharmaceuticals, Inc. — Director's Dealing 2021
Dec 7, 2021
35098_dirs_2021-12-06_12edf51a-3a98-426f-8bd9-f02a929dceac.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovaBay Pharmaceuticals, Inc. (NBY)
CIK: 0001389545
Period of Report: 2021-12-06
Reporting Person: Hall Justin (Director, CEO, GC and Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-06 | Common Stock | P | 69767 | $0.43 | Acquired | 73172 | Direct |
More from NovaBay Pharmaceuticals, Inc.
Regulatory Filings
2026
May 20
Interim / Quarterly Report
2026
May 15
Annual Report
2026
Apr 29
Regulatory Filings
2026
Apr 6
Regulatory Filings
2026
Apr 1
Regulatory Filings
2026
Mar 23
Annual Report
2026
Mar 19
Regulatory Filings
2026
Feb 20
Regulatory Filings
2026
Feb 12
Proxy Solicitation & Information Statement
2026
Feb 10